Posted by Michael Wonder on 14 Feb 2022
US FDA grants the coveted breakthrough designation for early stage prostate cancer detection blood test developed in India by Datar Cancer Genetics
14 February 2022 - It is the first blood test able to detect early stage prostate cancer with high accuracy in men aged 55 years and above.
Datar Cancer Genetics today announced that the US FDA has granted 'breakthrough designation' for its blood test to detect early-stage prostate cancer.
